Literature DB >> 10720075

Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins.

A Bansal1, D K Murray, J T Wu, R A Stephenson, R G Middleton, A W Meikle.   

Abstract

Both benign prostatic hyperplasia and prostate-specific antigen (PSA) have been shown to increase with age and with prostate volume in men, but the influence of heredity on these relationships is not completely understood. This study has two aims: 1) to investigate the inter-relationships of age, PSA, and various zonal measurements in the prostate; and 2) to assess the impact of heritable influences on total PSA. Eighty-four monozygotic twin pairs and 83 dizygotic twin pairs were studied, and serum total PSA, free PSA, and PSA-alpha1-antichymotrypsin were measured. Their prostate volumes [total (TV), transition zone (TZ), and peripheral zone) were quantitated using transrectal ultrasound. Total PSA is significantly correlated with all zonal prostate measurements (TZ, peripheral zone, TV, and TZ/TV) and with age. When linear regression was applied, only age and TZ were retained in the final model. The proportion of variability in total PSA explained by these two factors, however, is below 24%. In contrast, estimates of heritability show that approximately 45% of the variability in total PSA can be explained by inherited factors. Whereas age and TZ are linearly related to total PSA, their influence is much less than that of familial and genetic factors. It is uncertain whether these factors predispose also to prostate cancer or if they are independent of those, whether they confound the accuracy of using total serum PSA level as a diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720075     DOI: 10.1210/jcem.85.3.6399

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Authors:  Brian T Helfand; Carly A Conran; Jianfeng Xu; William J Catalona
Journal:  Curr Opin Urol       Date:  2017-09       Impact factor: 2.309

Review 2.  A genetic-based approach to personalized prostate cancer screening and treatment.

Authors:  Brian T Helfand; William J Catalona; Jianfeng Xu
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

3.  Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men.

Authors:  Nicholas M Donin; Stacy Loeb; Phillip R Cooper; Kimberly A Roehl; Nikola A Baumann; William J Catalona; Brian T Helfand
Journal:  BJU Int       Date:  2014-07-15       Impact factor: 5.588

4.  Genetic correction of PSA values using sequence variants associated with PSA levels.

Authors:  Julius Gudmundsson; Soren Besenbacher; Patrick Sulem; Daniel F Gudbjartsson; Isleifur Olafsson; Sturla Arinbjarnarson; Bjarni A Agnarsson; Kristrun R Benediktsdottir; Helgi J Isaksson; Jelena P Kostic; Sigurjon A Gudjonsson; Simon N Stacey; Arnaldur Gylfason; Asgeir Sigurdsson; Hilma Holm; Unnur S Bjornsdottir; Gudmundur I Eyjolfsson; Sebastian Navarrete; Fernando Fuertes; Maria D Garcia-Prats; Eduardo Polo; Ionel A Checherita; Mariana Jinga; Paula Badea; Katja K Aben; Jack A Schalken; Inge M van Oort; Fred C Sweep; Brian T Helfand; Michael Davis; Jenny L Donovan; Freddie C Hamdy; Kristleifur Kristjansson; Jeffrey R Gulcher; Gisli Masson; Augustine Kong; William J Catalona; Jose I Mayordomo; Gudmundur Geirsson; Gudmundur V Einarsson; Rosa B Barkardottir; Eirikur Jonsson; Viorel Jinga; Dana Mates; Lambertus A Kiemeney; David E Neal; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Sci Transl Med       Date:  2010-12-15       Impact factor: 17.956

5.  Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer.

Authors:  Paul J Dluzniewski; Jianfeng Xu; Ingo Ruczinski; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-28       Impact factor: 4.254

6.  Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.

Authors:  Brian T Helfand; Stacy Loeb; Qiaoyan Hu; Phillip R Cooper; Kimberly A Roehl; Barry B McGuire; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

7.  Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.

Authors:  Jielin Sun; Sha Tao; Yong Gao; Tao Peng; Aihua Tan; Haiying Zhang; Xiaobo Yang; Xue Qin; Yanling Hu; Junjie Feng; Seong-Tae Kim; Xiaoling Lin; Yongming Wu; Ju Zhang; Zhixian Li; Li Li; Linjian Mo; Zhengjia Liang; Deyi Shi; Zhang Huang; Xianghua Huang; Ming Liu; Qian Liu; Shijun Zhang; S Lilly Zheng; Jianfeng Xu; Zengnan Mo
Journal:  Hum Genet       Date:  2012-12-27       Impact factor: 4.132

8.  Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.

Authors:  Rebecca Gilbert; Richard M Martin; David M Evans; Kate Tilling; George Davey Smith; John P Kemp; J Athene Lane; Freddie C Hamdy; David E Neal; Jenny L Donovan; Chris Metcalfe
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

Authors:  Thomas J Hoffmann; Michael N Passarelli; Rebecca E Graff; Nima C Emami; Lori C Sakoda; Eric Jorgenson; Laurel A Habel; Jun Shan; Dilrini K Ranatunga; Charles P Quesenberry; Chun R Chao; Nirupa R Ghai; David Aaronson; Joseph Presti; Tobias Nordström; Zhaoming Wang; Sonja I Berndt; Stephen J Chanock; Jonathan D Mosley; Robert J Klein; Mridu Middha; Hans Lilja; Olle Melander; Mark N Kvale; Pui-Yan Kwok; Catherine Schaefer; Neil Risch; Stephen K Van Den Eeden; John S Witte
Journal:  Nat Commun       Date:  2017-01-31       Impact factor: 14.919

Review 10.  The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Authors:  Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.